Portfolio category: Therapeutics

Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target devastating neurodegenerative diseases such as Huntington’s disease for which there are currently no disease-modifying treatments available.

Artica Therapeutics is a Dutch start-up biotech focused on the developement of insurmountable covalent compound to treat autoimmune disorders. The covalent approach essentially blocks the target in an irreversible manner with the aim of producing compounds with improved clinical efficacy.

Based in Germany, Complement Therapeutics is a cell & gene therapy company focused on addressing unmet needs in complement (important part of the immune system) mediated diseases. The lead asset is an AAV-2 gene therapy focused on blocking the lesions in dry age-related macular degeneration (dAMD). These lesions are a major cause of vision loss in patients. The company is also exploring some earlier-stage programs.

Sibylla Biotech is based in Milan, Italy and develops a computational modelling platform to discover new protein degraders.Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Coave Therapeutics is a French based clinical-stage biotech company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.Coave’s next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. 

Shorla Oncology is an Irish speciality pharma company developing new oncology therapeutic products. Shorla develops and commercializes innovative oncology drugs for cancer with a particular focus on women’s, pediatric and rare cancers.

Storm Therapeutics is a UK-based drug discovery company tackling oncology and other diseases through modulating RNA modifying enzymes. The company is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

Prexton is a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease. The company was acquired by Lundbeck in March 2018.

Fusion Pharmaceuticals is a clinical-stage company focused on developing next-generation radiopharmaceuticals as precision medicines to treat cancer. The company is headquartered in Toronto with a base in Boston. Fusion listed on NASDAQ on June 2020 and now trades as FUSN. 

Precision Biotics (previously Alimentary Health) developed microbiome-based healthcare and nutritional products for inflammatory and other conditions.The company was acquired by Novozymes in June 2020.

Xention is a cardiovascular biotech company, specialised in the discovery and development of ion channel-modulating drugs. Its assets have now been partnered with or acquired by pharmaceutical partners.

Covagen was a biotech company that developed a novel platform technology for the discovery and development of bispecific antibodies. The company was acquired by Janssen in 2014.

Agi Therapeutics was a specialty pharmaceutical company that was focused on the development and commercialisation of specialty drug products.
The company completed an IPO in 2006 and was subsequently acquired by Vidara Therapeutics.